Application of OLA1 in the treatment of ocular vascular abnormalities
By using the drugs prepared by OLA1 protein in the treatment of ophthalmic diseases, the rebirth of blood vessels in the retina and cornea is suppressed, and the problem of limitations in the treatment methods of ophthalmic diseases in the prior art is solved, effective inhibition of abnormal vascular proliferative diseases in the eyes is achieved, and complications of surgical treatment are reduced.
Patent Information
- Application Number
- CN202311227321.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-22
- Publication Date
- 2025-03-28
- Estimated Expiration
- 2043-09-22
AI Technical Summary
The treatment methods for ophthalmic diseases in the prior art are relatively limited, and surgical treatment is often used, and most of them are accompanied by complications such as intraocular infection, which brings great inconvenience to patients' lives.
Using OLA1 protein in the preparation of drugs for treating abnormal vascular proliferation in the ocular vascular disease, provides a new therapeutic strategy by inhibiting the regeneration of blood vessels in the retina and cornea.
Through in vivo experiments, OLA1 has an inhibitory effect on abnormal vascular hyperplasia in the retina and cornea, providing a new treatment strategy for clinical abnormal vascular hyperplasia in the ocular and reduces the complications caused by surgical treatment.